AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01777217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGRT with placebo
Trial: NCT03401944
Drug: TPN
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00503412
Drug: AZD2171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral 14C
Trial: NCT00607399
Drug: SGX523 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a dose escalation study
Trial: NCT00086411
Drug: placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patch containing no nicotine
Trial: NCT01027234
Drug: AZD8418
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT01027234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT00042666
Drug: LY317615
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg, oral, QD, up to six 28 day cycles
Trial: NCT00003783
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003783
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003783
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003783
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00904462
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
Trial: NCT01560637
Drug: UT-15C (treprostinil diolamine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UT-15C extended release oral tablet three times daily
Trial: NCT00064259
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01380535
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)
Trial: NCT01579565
Drug: OMS302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Trial: NCT01579565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Trial: NCT01359241
Drug: Usual diabetes treatment regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual non-insulin glucose lowering medications
Trial: NCT03881904
Drug: 0.075mg gestodene/0.03mg ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.
Trial: NCT02987907
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use normal saline 2ml I.A. during TACE
Trial: NCT03887455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly (once every 2 weeks) administered as i.v. infusion.
Trial: NCT03303989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
Trial: NCT02363725
Drug: Colchimax®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02363725
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00142948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02334150
Drug: CSEA (ropivocaine and sufentanil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
Trial: NCT04140695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID
Trial: NCT05345574
Drug: remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil as anaesthetic adjuvant
Trial: NCT02764541
Drug: Endocrine Therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04420130
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer.
Trial: NCT00851318
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate dose between 6 to 8 mg/week.
Trial: NCT02589665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00728208
Drug: GSK372475
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5mg for 28 days
Trial: NCT01438008
Drug: Placebo po
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (almost identical in color, consistency and odor placebo to the sucrose solution in identical packaging) The total amount of the study solution will be divided into 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure
Trial: NCT01559922
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of up to 2 study treatments administered 6 weeks apart
Trial: NCT01432145
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 15 mg/m2 taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.
Trial: NCT00664560
Drug: PN 400 (VIMOVO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg naproxen/20 mg esomeprazole bid
Trial: NCT00664560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill bid
Trial: NCT00664560
Drug: Rescue Antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid Tablets
Trial: NCT01853579
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).
Trial: NCT01853579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Trial: NCT00150319
Drug: Vfend®; I.V.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01814878
Drug: Tramadol HCl/Acetaminophen ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of ER (tramadol HCl \[75 mg\]/acetaminophen \[650 mg\]) will be administered at 0, 12, 24 and 36 hours
Trial: NCT01814878
Drug: Tramadol HCl/Acetaminophen IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of IR (tramadol HCl \[37.5 mg\]/acetaminophen \[325 mg\]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
Trial: NCT03645421
Drug: MEDI0382 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose
Trial: NCT03645421
Drug: MEDI0382 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose
Trial: NCT03645421
Drug: MEDI0382 300 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection in 1.0 mL pre filled syringe, 300 μg per dose, 1 dose
Trial: NCT03645421
Drug: PlaceboA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mL liquid formulation per Vial
Trial: NCT03645421
Drug: MEDI0382 50 ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection, 1.0 mL per vial, 50 ug
Trial: NCT03645421
Drug: PlaceboB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection in 1.0 mL pre-filled syringe.
Trial: NCT03139981
Drug: ASN002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of ASN002 for 28 days
Trial: NCT03139981
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for ASN002 for 28 days
Trial: NCT00484393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo applied prior to 1 injection
Trial: NCT00549263
Drug: SB797620
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01549886
Drug: Y-90-Zevalin
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 8 - Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
Trial: NCT04225052
Drug: YHP1903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YHP1903 Tab. 1mg
Trial: NCT01952548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02975999
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
Trial: NCT00856908
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolerable dose given twice daily
Trial: NCT00856908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolerable dose given twice daily
Trial: NCT01813994
Drug: Arm1: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection.
Trial: NCT00634725
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03550443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing an inert placebo
Trial: NCT01106859
Drug: Placebo (sublingual tablet)
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
Trial: NCT01106859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching zopiclone
Trial: NCT02292082
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00896558
Drug: GSK1322322/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1322322/placebo escalating doses from 500mg to 1500mg
Trial: NCT04343651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02808052
Drug: Minocin (minocycline) for Injection
RxNorm normalized name: minocycline Injection [Minocin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg IV Minocin given over 1 hour
Trial: NCT01623596
Drug: Disease Modifying therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01802658
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times inclusion M12 and M24 over two years.
Trial: NCT01802658
Drug: NA Cl
RxNorm normalized name: China clay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NACl 100 ml IV. 3 infusions. Administration 3 times inclusion M12, M24 over two years.
Trial: NCT00451035
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02441491
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, by vein once every day to try to help your blood cells grow faster.
Trial: NCT03354312
Drug: Articaine hydrochloride/epinephrine (adrenaline) hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cylinder vials with 1.7 ml solution for injection containing 68 mg articaine and 0.0102 mg epinephrine (1 ml contains 40 mg articaine and 0.006 mg epinephrine) will be used. Infiltration anesthesia for the upper jaw and infiltration or nerve block anesthesia for the lower jaw with articaine solution for injection according to SmPC. Adults can be treated with up to 7 mg articaine per kg of body weight per treatment session.
Trial: NCT02399033
Drug: Xihuang Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.
Trial: NCT00170768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily tablet (sham titration)
Trial: NCT01792713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00924430
Drug: Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin
RxNorm normalized name: .alpha.,.beta.'-diglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
Trial: NCT00924430
Drug: Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
Trial: NCT01944098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00835198
Drug: Dapsone; Tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
Trial: NCT00835198
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
Trial: NCT04171791
Drug: ABT-199 (venetoclax)
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will be enrolled into the study and receive venetoclax daily per the US FDA package insert guidelines of venetoclax, with dose escalation up to 400 mg. To minimize the risk of tumor lysis syndrome (TLS), and following the package insert directions for dose escalation over 5 weeks, the initial dose is 20 mg daily, and may be progressively increased as tolerated to 400 mg by week 5.
Trial: NCT00464061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT01271712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily (od), 3 weeks on/1 week off. Route of administration: oral
Trial: NCT01271712
Drug: Best supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
Trial: NCT00145184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill taken orally once per day for two months starting at enrollment.
Trial: NCT04376684
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive standard of care as per institutional protocol.
Trial: NCT03014310
Drug: AS03
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03 oil-in-water emulsion adjuvant.
Trial: NCT03014310
Drug: MF59
RxNorm normalized name: vaccine adjuvant emulsion MF59C.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
Trial: NCT01630252
Drug: PGL5001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
Trial: NCT01630252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
Trial: NCT01630252
Drug: PGL5001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
Trial: NCT01630252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
Trial: NCT02370485
Drug: LY2801653
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00700544
Drug: chemotherapy treatment (see arms)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy + maintenance chemotherapy
Trial: NCT00964912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, Oral, 0 mg, single dose, one dose
Trial: NCT02091531
Drug: MLN0128
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04142424
Drug: AZD2693
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive SC injection of AZD2693 as per the arms they are randomized.
Trial: NCT04142424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.
Trial: NCT02202213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02856243
Drug: new antiviral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00408863
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06454825
Drug: Intravenous drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medications were applied intravenously to the groups 30 minutes before end of the procedure
Trial: NCT03532854
Drug: Ezetimibe/Rosuvastatin
RxNorm normalized name: EZETIMIBE/ROSUVASTATIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/Rosuvastatin P.O
Trial: NCT03020134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo